A novel acylated form of (d-Ala2)GIP with improved antidiabetic potential, lacking effect on body fat stores

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

BACKGROUND: Rapid enzymatic degradation of the incretin hormone, glucose-dependent insulinotropic polypeptide (GIP), limits therapeutic use of the native peptide for diabetes. However, enzymatically stable analogues of GIP, such as (d-Ala2)GIP, have been generated, but are still susceptible to renal filtration.METHODS: The present study examines the in vitro and in vivo biological actions of a novel, acylated GIP analogue, (d-Ala2)GIP[Lys37PAL].RESULTS: In BRIN-BD11 cells, (d-Ala2)GIP[Lys37PAL] concentration-dependently stimulated (p
Original languageEnglish
Pages (from-to)3407-3413
JournalBIOCHIMICA ET BIOPHYSICA ACTA
Volume1830
Issue number6
DOIs
Publication statusPublished - 18 Jun 2013

Fingerprint Dive into the research topics of 'A novel acylated form of (d-Ala2)GIP with improved antidiabetic potential, lacking effect on body fat stores'. Together they form a unique fingerprint.

  • Cite this